Mobilisation strategies for normal and malignant cells

Pathology

Volumn 43, Issue 6, 2011, Pages 547-565

  Bik To, L ^a,b   Levesque, Jean Pierre ^c,d   Herbert, Kirsten E ^e,f   Winkler, Ingrid G ^c,d   Bendall, Linda J ^g   Hiwase, Devendra K ^a,b   Antonenas, Vicki ^h   Rice, Alison M ^c,d   Gottlieb, David ^g   Mills, Anthony K ^d,h   Rasko, John Ej ^i,j   Larsen, Stephen ^k   Beligaswatte, Ashanka ^a   Nilsson, Susan K ^j,k,l   Cooney, Julian P ^l,m,n   Cambareri, Antony C ^a   Lewis, Ian D ^a,b  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c MATER MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e PRINCESS ALEXANDRA HOSPITAL   (Australia)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g CABRINI INSTITUTE   (Australia)

^h CSIRO   (Australia)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j UNIVERSITY OF SYDNEY   (Australia)

^k WESTMEAD HOSPITAL   (Australia)

^l ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^m ROYAL PERTH HOSPITAL   (Australia)

ⁿ UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

more..

Author keywords

Haemopoietic stem cells; Immune cells; Leukaemic cells; Mobilisation

Indexed keywords

EID: 83055182199     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e32834a9eb8     Document Type: Review

References (261)

1. Goodman JW, Hodgson GS. Evidence for stem cells in the peripheral blood ofmice. Blood 1962; 19: 702-14.
2. Mc Credie KB, Hersh EM, Freireich EJ. Cells capable of colony formation in the peripheral blood ofman. Science 1971; 171: 293-4.
3. Micklem HS, Anderson N, Ross E. Limited potential of circulating haemopoietic stem cells. Nature 1975; 256: 41-3.
4. Hershko C, Gale RP, Ho WG, Cline MJ. Cure of aplastic anaemia in paroxysmal nocturnal haemoglobinuria by marrow transfusion from identical twin: Failure of peripheral-leucocyte transfusion to correct marrow aplasia. Lancet 1979; 1: 945-7. (Pubitemid 9163644)
5. Abrams RA, Glaubiger D, Appelbaum FR, Deisseroth AB. Result of attempted hematopoietic reconstitution using isologous, peripheral blood mononuclear cells: a case report. Blood 1980; 56: 516-20. (Pubitemid 11251035)
6. Abrams RA, Mc Cormack K, Bowles C, Deisseroth AB. Cyclophospha-mide treatment expands the circulating hematopoietic stem cell pool in dogs. J Clin Invest 1981; 67: 1392-9. (Pubitemid 11099353)
7. Lohrmann HP, Schreml W, Fliedner TM, Heimpel H. Reaction of human granulopoiesis to high-dose cyclophosphamide therapy. Blut 1979; 38: 9-16. (Pubitemid 9109995)
8. Richman CM, Weiner RS, Yankee RA. Increase in circulating stem cells following chemotherapy in man. Blood 1976; 47: 1031-9.
9. To LB, Haylock DN, Kimber RJ, Juttner CA. High levels of circulating haemopoietic stem cells in very early remission from acute non-lympho-blastic leukaemia and their collection and cryopreservation. Br J Hae-matol 1984; 58: 399-410. (Pubitemid 14017189)
10. Juttner CA, To LB, Haylock DN, et al. Circulating autologous stem cells collected in very early remission from acute non-lymphoblastic leukaemia produce prompt but incomplete haemopoietic reconstitution after high dose melphalan or supralethal chemoradiotherapy. Br J Haematol 1985; 61: 739-45. (Pubitemid 16231526)
11. To LB, Shepperd KM, Haylock DN, et al. Single high doses of cyclopho-sphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol 1990; 18: 442-7. (Pubitemid 20250496)
12. Sheridan WP, Begley CG, Juttner CA, et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640-4.
13. To LB, Roberts MM, Haylock DN, et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Trans-plant 1992; 9: 277-84.
14. Grigg AP, Roberts AW, Raunow H, et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 1995; 86: 4437-45.
15. Begley CG, Basser R, Mansfield R, et al. Enhanced levels and enhanced clonogenic capacity of blood progenitor cells following administration of stem cell factor plus granulocyte colony-stimulating factor to humans. Blood 1997; 90: 3378-89. (Pubitemid 27473406)
16. Basser RL. New developments in high-dose chemotherapy for breast cancer. Recent Results Cancer Res 1998; 152: 355-67.
17. Basser RL, To LB, Collins JP, et al. Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage II or III breast cancer: five-year follow-up. J Clin Oncol 1999; 17: 82-92. (Pubitemid 29022381)
18. To LB, Bashford J, Durrant S, et al. Successful mobilization ofperipheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim. Bone Marrow Transplant 2003; 31: 371-8. (Pubitemid 36410683)
19. Herbert KE, Morgan S, Prince HM, et al. Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders pre-viously treated with fludarabine: results of a Phase II study with an historical comparator. Leukaemia 2009; 23: 305-12.
20. To LB, Dyson PG, Juttner CA. Cell-dose effect in circulating stem-cell autografting. Lancet 1986; 2: 404-5. (Pubitemid 16036539)
21. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses ofblood stem cells. Blood 1997; 89: 2233-58. (Pubitemid 27143269)
22. Schulman KA, Birch R, Zhen B, et al. Effect of CD34(+) cell dose on resource utilization in patients after high-dose chemotherapy with per-ipheral-blood stem-cell support. J Clin Oncol 1999; 17: 1227.
23. Heimfeld S. Bone marrow transplantation: how important is CD34 cell dose in HLA-identical stem cell transplantation? Leukaemia 2003; 17: 856-8. (Pubitemid 36626311)
24. Siegel DS, Desikan KR, Mehta J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999; 93: 51-4. (Pubitemid 29019387)
25. Michallet M, Thiebaut A, Dreger P, et al. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP). Br J Haematol 2000; 108: 595-601. (Pubitemid 30196258)
26. Tournilhac O, Cazin B, Lepretre S, et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukaemia. Blood 2004; 103: 363-5. (Pubitemid 38029961)
27. Lysak D, Koza V, Steinerova K, et al. Mobilization of peripheral blood stem cells in CLL patients after front-line fludarabine treatment. Ann Hematol 2005; 84: 456-61. (Pubitemid 40867922)
28. Jantunen E, Itala M, Siitonen T, et al. Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis. Bone Marrow Transplant 2008; 41: 239-44. (Pubitemid 351260377)
29. Cancelas JA, Jansen M, Williams DA. The role of chemokine activation of Rac GTPases in hematopoietic stem cell marrow homing, retention, and peripheral mobilization. Exp Hematol 2006; 34: 976-85. (Pubitemid 44080381)
30. Papayannopoulou T, Priestley GV, Bonig H, Nakamoto B. The role of G-protein signaling in hematopoietic stem/progenitor cell mobilization. Blood 2003; 101: 4739-47. (Pubitemid 36857730)
31. Mendez-Ferrer S, Frenette PS. Galpha(s) uncouples hematopoietic stem cell homing and mobilization. Cell Stem Cell 2009; 4: 379-80.
32. Levesque JP, Helwani FM, Winkler IG. The endosteal 'osteoblastic' niche and its role in hematopoietic stem cell homing and mobilization. Leukaemia 2010; 24: 1979-92.
33. Tzeng Y-S, Li H, Kang Y-L, et al. Loss of Cxcl12/Sdf-1 in adult mice decreases the quiescent state of hematopoietic stem/progenitor cells and alters the pattern of hematopoietic regeneration after myelosuppression. Blood 2011; 117: 429-39.
34. Ulyanova T, Scott LM, Priestley GV, et al. VCAM-1 expression in adult hematopoietic and nonhematopoietic cells is controlled by tissue-induc-tive signals and reflects their developmental origin. Blood 2005; 106: 86-94. (Pubitemid 40967178)
35. Broxmeyer HE, Orschell CM, Clapp DW, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005; 201: 1307-18. (Pubitemid 40629073)
36. Nakamura Y, Tajima F, Ishiga K, et al. Soluble c-kit receptor mobilizes hematopoietic stem cells to peripheral blood in mice. Exp Hematol 2004; 32: 390-6. (Pubitemid 38410916)
37. Ramirez P, Rettig MP, Uy GL, et al. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood 2009; 114: 1340-3.
38. Bonig H, Wundes A, Chang KH, et al. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 2008; 111: 3439-41.
39. Levesque JP, Hendy J, Takamatsu Y, et al. Disruption of the CXCR4/ CXCL12 chemotactic interaction during hematopoietic stem cell mobi-lization induced by GCSF or cyclophosphamide. J Clin Invest 2003; 111: 187-96. (Pubitemid 36105917)
40. Levesque JP, Hendy J, Takamatsu Y, et al. Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. Exp Hematol 2002; 30: 440-9. (Pubitemid 34556735)
41. Levesque JP, Hendy J, Winkler IG, et al. Granulocyte colony-stimulating factor induces the release in the bone marrow of proteases that cleave c-KIT receptor (CD117) from the surface of hematopoietic progenitor cells. Exp Hematol 2003; 31: 109-17. (Pubitemid 36184635)
42. Levesque JP, Takamatsu Y, Nilsson SK, et al. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granu-locyte colony-stimulating factor. Blood 2001; 98: 1289-97.
43. Christopherson K, Cooper S, Hangoc G, Broxmeyer H. CD26 is essential for normal G-CSF-induced progenitor cell mobilization as determined by CD26-/- mice. Exp Hematol 2003; 31: 1126-34. (Pubitemid 37329758)
44. Ratajczak J, Reca R, Kucia M, et al. Mobilization studies in mice deficient in either C3 or C3a receptor (C3a R) reveal a novel role for complement in retention of hematopoietic stem/progenitor cells in bone marrow. Blood 2004; 103: 2071-8. (Pubitemid 38326222)
45. Lee HM, Wu W, Wysoczynski M, et al. Impaired mobilization of hematopoietic stem/progenitor cells in C5-deficient mice supports the pivotal involvement of innate immunity in this process and reveals novel promobilization effects ofgranulocytes. Leukaemia 2009; 23: 2052-62.
46. Tjwa M, Janssens S, Carmeliet P. Plasmin therapy enhances mobilization of HPCs after G-CSF. Blood 2008; 112: 4048-50.
47. Liu F, Poursine-Laurent J, Link DC The granulocyte colony-stimulating factor receptor is required for the mobilization of murine hematopoietic progenitors into peripheral blood by cyclophosphamide or interleukin-8 but not flt-3 ligand. Blood 1997; 90: 2522-8. (Pubitemid 27413459)
48. Pelus LM, Bian H, King AG, Fukuda S. Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GRO ß/CXCL2 and GROßT /CXCL2Δ4. Blood 2004; 103: 110-9. (Pubitemid 38029925)
49. Levesque JP, Liu F, Simmons PJ, et al. Characterization ofhematopoietic progenitor mobilization in protease-deficient mice. Blood 2004; 104: 65-72. (Pubitemid 38879839)
50. Calado RT, Young NS. Telomere maintenance and human bone marrow failure. Blood 2008; 111: 4446-55.
51. Mayack SR, Shadrach JL, Kim FS, Wagers AJ. Systemic signals regulate ageing and rejuvenation of blood stem cell niches. Nature 2010; 463: 495-500.
52. Zhu J, Garrett R, Jung Y, et al. Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cells. Blood 2007; 109: 3706-12. (Pubitemid 46641719)
53. Roberts AW, Foote S, Alexander WS, et al. Genetic influences determin-ing progenitor cell mobilization and leukocytosis induced by granulocyte colony-stimulating factor. Blood 1997; 89: 2736-44. (Pubitemid 27172558)
54. Geiger H, Szilvassy SJ, Ragland P, Van Zant G. Genetic analysis of progenitor cell mobilization by granulocyte colony-stimulating factor: verification and mechanisms for loci on murine chromosomes 2 and 11. Exp Hematol 2004; 32: 60-7. (Pubitemid 38064402)
55. Winkler IG, Sims NA, Pettit AR, et al. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood 2010; 116: 4815-28.
56. Chow A, Lucas D, Hidalgo A, et al. Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J Exp Med 2011; 208: 261-71.
57. Christopher MJ, Rao M, Liu F, et al. Expression of the G-CSF receptor in monocytic cells is sufficient to mediate hematopoietic progenitor mobi-lization by G-CSF in mice. J Exp Med 2011; 208: 251-60.
58. Chang MK, Raggatt LJ, Alexander KA, et al. Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo. J Immunol 2008; 181: 1232-44.
59. Ehninger A, Trumpp A. The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in. J Exp Med 2011; 208: 421-8.
60. Ratajczak MZ, Lee H, Wysoczynski M, et al. Novel insight into stem cell mobilization-plasma sphingosine-1-phosphate is amajor chemoattractant that directs the egress of hematopoietic stem progenitor cells from the bone marrow and its level in peripheral blood increases during mobiliza-tion due to activation of complement cascade/membrane attack complex. Leukaemia 2010; 24: 976-85.
61. Mendez-Ferrer S, Lucas D, Battista M, Frenette PS. Haematopoietic stem cell release is regulated by circadian oscillations. Nature 2008; 452: 442-7. (Pubitemid 351450836)
62. Lucas D, Battista M, Shi PA, et al. Mobilized hematopoietic stem cell yield depends on species-specific circadian timing. Cell Stem Cell 2008; 3: 364-6.
63. Katayama Y, Battista M, Kao WM, et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell 2006; 124: 407-21. (Pubitemid 43121987)
64. To LB, Levesque JP, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood 2011; Aug 10; (Epub ahead of print).
65. Larsen SR, Chng K, Battah F, et al. Improved granulocyte colony-stimulating factor mobilization of hemopoietic progenitors using cytokine combinations in primates. Stem Cells 2008; 26: 2974-80.
66. Rowlings PA, Bayly JL, Rawling CM, et al. A comparison of peripheral blood stem cell mobilisation after chemotherapy with cyclophosphamide as a single agent in doses of 4g/m or 7g/m in patients with advanced cancer. Aust N Z J Med 1992; 22: 660-4.
67. Hiwase DK, Bollard G, Hiwase S, et al. Intermediate-dose CYand G-CSF more efficiently mobilize adequate numbers of PBSC for tandem auto-logous PBSC transplantation compared with low-dose CYin patients with multiple myeloma. Cytotherapy 2007; 9: 539-47. (Pubitemid 47457005)
68. Schwartzberg LS, Birch R, Hazelton B, et al. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. J Hematother 1992; 1: 317-27.
69. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 4184-90.
70. Gertz MA, Kumar SK, Lacy MQ, et al. Comparison ofhigh-dose CYand growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Trans-plant 2009; 43: 619-25.
71. Arora M, Burns LJ, Barker JN, et al. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Biol Blood Marrow Transplant 2004; 10: 395-404. (Pubitemid 38647288)
72. Dingli D, Nowakowski GS, Dispenzieri A, et al. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin Lymphoma Myeloma 2006; 6: 384-8.
73. Andre M, Baudoux E, Bron D, et al. Phase III randomized study comparing 5 or 10 microg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies. Transfusion 2003; 43: 50-7. (Pubitemid 36322896)
74. Lefrere F, Zohar S, Bresson JL, et al. A double-blind low dose-finding phase II study of granulocyte colony-stimulating factor combined with chemotherapy for stem cell mobilization in patients with non-Hodgkin's lymphoma. Haematologica 2006; 91: 550-3.
75. Engelhardt M, Bertz H, Afting M, et al. High-versus standard-dose filgrastim (rh G-CSF) for mobilization ofperipheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection. J Clin Oncol 1999; 17: 2160-72. (Pubitemid 29318849)
76. Kroger N, Renges H, Kruger W, et al. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br J Haematol 2000; 111: 761-5. (Pubitemid 32098912)
77. Kroger N, Sonnenberg S, Cortes-Dericks L, et al. Kinetics of G-CSF and CD34+ cell mobilization after once or twice daily stimulation with r Hu granulocyte-stimulating factor (lenograstim) in healthy volunteers: an intraindividual crossover study. Transfusion 2004; 44: 104-10. (Pubitemid 38177144)
78. Anderlini P, Donato M, Lauppe MJ, et al. A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors. Br J Haematol 2000; 109: 770-2. (Pubitemid 30609754)
79. Hoglund M, Smedmyr B, Bengtsson M, et al. Mobilization of CD34+ cells by glycosylated and nonglycosylated G-CSF in healthy volunteers-a comparative study. Eur J Haematol 1997; 59: 177-83. (Pubitemid 27392094)
80. Lefrere F, Bernard M, Audat F, et al. Comparison of lenograstim vs filgrastim administration following chemotherapy for peripheral blood stem cell (PBSC) collection: a retrospective study of 126 patients. Leuk Lymphoma 1999; 35: 501-5. (Pubitemid 30015649)
81. Fischer JC, Frick M, Wassmuth R, et al. Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors. Br J Haematol 2005; 130: 740-6. (Pubitemid 43906646)
82. Hill GR, Morris ES, Fuery M, et al. Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF. Biol Blood Marrow Transplant 2006; 12: 603-7.
83. Kroschinsky F, Holig K, Poppe-Thiede K, et al. Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors. Haematologica 2005; 90: 1665-71. (Pubitemid 41814992)
84. Ballestrero A, Ferrando F, Garuti A, et al. Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte col-ony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF. J Clin Oncol 1999; 17: 1296.
85. De La Rubia J, Lorenzo JI, Torrabadella M, et al. Basal CD34(+) cell count predicts peripheral blood progenitor cell mobilization and collection in healthy donors after administration of granulocyte colony-stimulating factor. Haematologica 2004; 89: 1530-2. (Pubitemid 39643525)
86. Suzuya H, Watanabe T, Nakagawa R, et al. Factors associated with granulocyte colony-stimulating factor-induced peripheral blood stem cell yield in healthy donors. Vox Sang 2005; 89: 229-35. (Pubitemid 41641103)
87. Martino M, Callea I, Condemi A, et al. Predictive factors that affect the mobilization of CD34(+) cells in healthy donors treated with recombinant granulocyte colony-stimulating factor (G-CSF). J Clin Apher 2006; 21: 169-75. (Pubitemid 46579291)
88. Namba N, Matsuo K, Kubonishi S, et al. Prediction of number of apheresis procedures necessary in healthy donors to attain minimally required peripheral blood CD34+ cells. Transfusion 2009; 49: 2384-9.
89. Akhtar S, Weshi AE, Rahal M, et al. Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: a single institution result of 168 patients. Leuk Lymphoma 2008; 49: 769-78. (Pubitemid 351517224)
90. Micallef IN, Apostolidis J, Rohatiner AZ, et al. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J 2000; 1: 367-73.
91. Perry AR, Watts MJ, Peniket AJ, et al. Progenitor cell yields are frequently poor in patients with histologically indolent lymphomas especially when mobilized within 6 months of previous chemotherapy. Bone Marrow Transplant 1998; 21: 1201-5. (Pubitemid 28318746)
92. Ameen RM, Alshemmari SH, Alqallaf D. Factors associated with success-ful mobilization of progenitor hematopoietic stem cells among patients withlymphoidmalignancies. Clin Lymphoma Myeloma2008; 8: 106-10. (Pubitemid 351775768)
93. Itala M, Pelliniemi TT, Rajamaki A, Remes K. Autologous blood cell transplantation in B-CLL: response to chemotherapy prior to mobilization predicts the stem cell yield. Bone Marrow Transplant 1997; 19: 647-51. (Pubitemid 27182486)
94. Pavone V, Gaudio F, Console G, et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 37: 719-24.
95. Koenigsmann M, Jentsch-Ullrich K, Mohren M, et al. The role of diagnosis in patients failing peripheral blood progenitor cell mobilization. Transfusion 2004; 44: 777-84. (Pubitemid 38608258)
96. Kuittinen T, Nousiainen T, Halonen P, et al. Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Trans-plant 2004; 33: 907-12. (Pubitemid 38660123)
97. Fu P, Bagai RK, Meyerson H, et al. Pre-mobilization therapy blood CD34+ cell count predicts the likelihood of successful hematopoietic stem cell mobilization. Bone Marrow Transplant 2006; 38: 189-96. (Pubitemid 44102945)
98. Hosing C, Saliba RM, Ahlawat S, et al. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 2009; 84: 335-7.
99. Putkonen M, Rauhala A, Pelliniemi TT, Remes K. Sepsis, low platelet nadir at mobilization and previous IFN use predict stem cell mobilization failure in patients with multiple myeloma. Cytotherapy 2007; 9: 548-54. (Pubitemid 47457006)
100. Ozkurt ZN, Yegin ZA, Suyani E, et al. Factors affecting stem cell mobilization for autologous hematopoietic stem cell transplantation. J Clin Apher 2010; 25: 280-6.
101. Corso A, Varettoni M, Mangiacavalli S, et al. Bone marrow CD34+ cell count is predictive for adequate peripheral progenitor cell collection. Leuk Res 2005; 29: 159-63. (Pubitemid 39647510)
102. Damiani D, Grimaz S, Sperotto A, et al. The use of G-CSF during first line chemotherapy adversely affects the yield of PBSC mobilization in non-Hodgkin's lymphoma patients. Adv Clin Pathol 2002; 6: 11-6.
103. Goldschmidt H, Hegenbart U, Wallmeier M, et al. Factors influencing collection of peripheral blood progenitor cells following high-dose cy-clophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 1997; 98: 736-44. (Pubitemid 27386558)
104. Clark RE, Brammer CG. Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system. Bone Marrow Transplant 1998; 22: 859-63. (Pubitemid 28499358)
105. Canales MA, Fernandez-Jimenez MC, Martin A, et al. Identification of factors associated with poor peripheral blood progenitor cell mobilization in Hodgkin's disease. Haematologica 2001; 86: 494-8. (Pubitemid 33638977)
106. Drake M, Ranaghan L, Morris TC, et al. Analysis of the effect of prior therapy on progenitor cell yield: use of a chemotherapy scoring system. Br J Haematol 1997; 98: 745-9. (Pubitemid 27386559)
107. Jantunen E, Kuittinen T, Nousiainen T. Is chemotherapy scoring useful to predict progenitor cell mobilisation in patients with non-Hodgkin's lym-phoma? Bone Marrow Transplant 2003; 32: 569-73. (Pubitemid 37185091)
108. Haas R, Mohle R, Fruhauf S, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-94. (Pubitemid 24175570)
109. Demirer T, Buckner CD, Gooley T, et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 937-41. (Pubitemid 26235837)
110. Koumakis G, Vassilomanolakis M, Hatzichristou H, et al. Predictive factors affecting mobilization and peripheral blood stem cell (PBSC) collection using single apheresis (SA) for rescuing patients after high-dose chemotherapy (HD.CHE) in various malignancies. Bone Marrow Transplant 1996; 18: 1065-72.
111. Morton J, Morton A, Bird R, et al. Predictors for optimal mobilization and subsequent engraftment of peripheral blood progenitor cells following intermediate dose cyclophosphamide and G-CSF. Leuk Res 1997; 21: 21-7. (Pubitemid 27073238)
112. Rinn JP, Schwella N, Wollmer E, et al. Local irradiation prior to stem cell harvest has no influence on CD34+ yield: a quantitative analysis. Ann Hematol 2006; 85: 38-44. (Pubitemid 41782424)
113. Auner HW, Mazzarella L, Cook L, et al. High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induc-tion therapy for multiple myeloma. Bone Marrow Transplant 2011; 46: 364-7.
114. Popat U, Saliba R, Thandi R, et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 2009; 15: 718-23.
115. Micallef IN, Ho AD, Klein LM, et al. Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide. Bone Marrow Transplant 2011; 46: 350-5.
116. Lysák D, Hrabetová M, Vrzalová J, et al. Changes of cytokine levels during granulocyte-colony-stimulating factor stem cell mobilization in healthy donors: association with mobilization efficiency and potential predictive significance. Transfusion 2011; 51: 319-27.
117. Sinha S, Gastineau D, Micallef I, et al. Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. Bone Marrow Transplant 2010.
118. Petit I, Szyper-Kravitz M, Nagler A, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002; 3: 687-94. (Pubitemid 34752479)
119. Liles WC, Rodger E, Broxmeyer HE, et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005; 45: 295-300. (Pubitemid 40389423)
120. Donzella GA, Schols D, Lin SW, et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 1998; 4: 72-7. (Pubitemid 28133082)
121. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization ofhematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102: 2728-30. (Pubitemid 37248839)
122. Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lym-phoma. J Clin Oncol 2004; 22: 1095-102. (Pubitemid 41095043)
123. Flomenberg N, Devine SM, Di Persio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867-74. (Pubitemid 41208607)
124. Calandra G, Mc Carty J, Mc Guirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassio-nate use data. Bone Marrow Transplant 2008; 41: 331-8. (Pubitemid 351330727)
125. Micallef IN, Stiff PJ, Di Persio JF, et al. Successful stem cell remobiliza-tion using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. Biol Blood Marrow Transplant 2009; 15: 1578-86.
126. Di Persio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-6.
127. Ehninger G, Fruehauf S, Hubel K, et al. Steady state mobilisation of autologous blood stem cells using G-CSF and AMD3100 in patients with multiple myeloma (MM). ASH Annual Meeting Abstracts 2006; 108: 5219.
128. Tricot G, Cottler-Fox MH, Calandra G. Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant 2010; 45: 63-8.
129. Stiff P, Micallef I, McCarthy P, et al. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant 2009; 15: 249-56.
130. Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV, Stuart RK. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011; 46: 64-9.
131. Costa LJ, Miller AN, Alexander ET, et al. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for auto-logous hematopoietic stem cells mobilization. Bone Marrow Transplant 2011; 46: 523-8.
132. Alexander ET, Towery JA, Miller AN, et al. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization
133. Duong HK, Bolwell BJ, Rybicki L, et al. Predicting hematopoietic stem cell mobilization failure in patients with multiple myeloma: A simple method using day 1 CD34+ cell yield. J Clin Apher 2011; 26: 111-5.
134. Herbert KE, Levesque JP, Mills AK, et al. How we mobilize haemopoietic stem cells. Intern Med J 2011; 41: 588-94.
135. Schmitt S, Weinhold N, Dembowsky K, et al. First results of a phase-II study with the new CXCR4 antagonist POL6326 to mobilize hemato-poietic stem cells (HSC) in multiple myeloma (MM). ASH Annual Meeting Abstracts 2010; 116: 824.
136. Nagler A, Shimoni A, Avivi I, et al. BKT140 is a novel CXCR4 antagonist with stem cell mobilization and antimyeloma effects: an open-label first human trial in patients with multiple myeloma undergoing stem cell mobilization for autologous transplantation. ASH Annual Meeting Ab-stracts 2010; 116: 2260.
137. Kim C, Wan W, Liu R, et al. A novel paradigm in stem cell trafficking: the ratio ofperipheral blood sphingosine-1 phosphate (S1P) to bone marrow ceramide-1 phosphate (C1P) regulates mobilization and homing of he-matopoietic stem cells. ASH Annual Meeting Abstracts 2010; 116: 554.
138. Brasel K, McKenna HJ, Charrier K, et al. Synergisticeffectsinvivo offlt3 ligand with GM-CSF of G-CSF in mobilisation of colony forming cells in mice. Blood 1995; 86: 449a.
139. Rasko JE, Basser RL, Boyd J, et al. Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG-r Hu MGDF. Br J Haematol 1997; 97: 871-80. (Pubitemid 27321390)
140. Kuter DJ. Biology and chemistry of thrombopoietic agents. Semin He-matol 2010; 47: 243-8.
141. Dreger P, Haferlach T, Eckstein V, et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol 1994; 87: 609-13. (Pubitemid 24230031)
142. Li J, Hamilton E, Vaughn L, et al. Effectiveness and cost analysis of 'just-in-time' salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion 2011; Apr 14: (Epub ahead ofprint).
143. Kobbe G, Bruns I, Fenk R, et al. Pegfilgrastim for PBSC mobilization and autologoushaematopoietic SCT. Bone Marrow Transplant2009; 43: 669-77
144. National Pathology Accreditation Advisory Council (NPAAC). Require-mentsfor Procedures Related to the Collection, Processing, Storage and Issue of Human Haemopoietic Progenitor Cells (Third Edition 2009). Canberra: Australian Government Department of Health and Ageing, 2009. http://www.health.gov.au/internet/main/publishing.nsf/Content/ health-npaac-docs-human-haemopoietic.htm
145. Foundation for the Accreditation of Cellular Therapy and the Joint Accreditation Committee - ISCT and EBMT. FACT-JACIE International Standards for Cellular Therapy Products Collection, Processing and Administration. Omaha: Foundation for the Accreditation of Cellular Therapy, 2008. http://www. factwebsite.org/Standards/
146. Fois E, Desmartin M, Benhamida S, et al. Recovery, viability and clinical toxicity ofthawed and washed haematopoietic progenitor cells: analysis of 952 autologous peripheral blood stem cell transplantations. Bone Marrow Transplant 2007; 40: 831-5. (Pubitemid 350020316)
147. Cordoba R, Arrieta R, Kerguelen A, Hernandez-Navarro F. The occur-rence of adverse events during the infusion of autologous peripheral blood stem cells is related to the number of granulocytes in the leukapheresis product. Bone Marrow Transplant 2007; 40: 1063-7. (Pubitemid 350142560)
148. Antonenas V, Garvin F, Webb M, et al. Fresh PBSC harvests, but not BM, show temperature-related loss of CD34 viability during storage and transport. Cytotherapy 2006; 8: 158-65. (Pubitemid 43675202)
149. Sutherland DR, Nayyar R, Acton E, et al. Comparison of two single-platform ISHAGE-based CD34 enumeration protocols on BD FACSCa-libur and FACSCanto flow cytometers. Cytotherapy 2009; 11: 595-605.
150. Chang A, Raik E, Marsden K, Ma DD. Australasian CD34+ quality assurance program and rationale for the clinical utility of the single-platform method for CD34+ cell enumeration. Cytotherapy 2004; 6: 50-61. (Pubitemid 38325119)
151. Rowley SD, Bensinger WI, Gooley TA, Buckner CD. Effect of cell concentration on bone marrow and peripheral blood stem cell cryopre-servation. Blood 1994; 83: 2731-6. (Pubitemid 24135868)
152. Sartor M, Antonenas V, Garvin F, et al. Recovery of viable CD34+ cells from cryopreserved hemopoietic progenitor cell products. Bone Marrow Transplant 2005; 36: 199-204. (Pubitemid 41136291)
153. Kawano Y, Lee CL, Watanabe T, et al. Cryopreservation of mobilized blood stem cells at a higher cell concentration without the use of a programmed freezer. Ann Hematol 2004; 83: 50-4. (Pubitemid 38088237)
154. Australian Bone Marrow Donor Registry (ABMDR) Website. July 2011 (cited July 2011). http://www.abmdr.org.au
155. Powles R, Singhal S, Treleaven J, et al. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukaemia on the basis of lymphocyte recovery early after transplantation. Blood 1998; 91: 3481-6. (Pubitemid 28193902)
156. Dazzi F, Szydlo RM, Craddock C, et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukaemia. Blood 2000; 95: 67-71. (Pubitemid 30017226)
157. Dazzi F, Szydlo RM, Cross NC, et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia. Blood 2000; 96: 2712-6.
158. Hiwase DK, Hiwase S, Bailey M, et al. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplan-tation for multiple myeloma. Biol Blood Marrow Transplant 2008; 14: 116-24. (Pubitemid 350286748)
159. Porrata LF, Gertz MA, Inwards DJ, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell Transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001; 98: 579-85.
160. Kim H, Sohn HJ, Kim S, et al. Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006; 37: 1037-42.
161. Kim H, Sohn HJ, Kim SE, et al. Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 34: 43-9. (Pubitemid 39022956)
162. Joao C, Porrata LF, Inwards DJ, et al. Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma. Bone Marrow Transplant 2006; 37: 865-71.
163. Boulassel MR, Herr AL, de BEMD, et al. Early lymphocyte recovery following autologous peripheral stem cell transplantation is associated with better survival in younger patients with lymphoproliferative disor-ders. Hematology 2006; 11: 165-70. (Pubitemid 44355696)
164. Yoong Y, Porrata LF, Inwards DJ, et al. The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplanta-tion for non-Hodgkin's lymphoma. Leuk Lymphoma 2005; 46: 1287-94. (Pubitemid 41269294)
165. Gordan LN, Sugrue MW, Lynch JW, et al. Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell Transplant in patients with Hodgkin's and non-Hodgkin's Lymphoma. Bone Marrow Transplant 2003; 31: 1009-13. (Pubitemid 36722413)
166. Porrata LF, Inwards DJ, Micallef IN, et al. Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. Br J Haematol 2002; 117: 629-33. (Pubitemid 34539239)
167. Porrata LF, Gertz MA, Litzow MR, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell Transplantation for patients with primary systemic amyloidosis. Clin Cancer Res 2005; 11: 1210-8. (Pubitemid 40175773)
168. Porrata LF, Inwards DJ, Ansell SM, et al. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant 2008; 14: 807-16. (Pubitemid 351773157)
169. Porrata LF, Gertz MA, Geyer SM, et al. The dose ofinfused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukaemia 2004; 18: 1085-92. (Pubitemid 38786967)
170. Porrata LF, Litzow MR, Inwards DJ, et al. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral he-matopoietic stem cell transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 291-8. (Pubitemid 38256560)
171. Porrata LF, Gastineau DA, Padley D, et al. Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation. Leuk Lymphoma 2003; 44: 997-1000. (Pubitemid 36416999)
172. Schmidmaier R, Oversohl N, Schnabel B, et al. Helper T cells (CD3 + / CD4 +) within the autologous peripheral blood stem cell graft positively correlate with event free survival of multiple myeloma patients. Exp Oncol 2008; 30: 240-3.
173. Atta EH, de Azevedo AM, Maiolino A, et al. High CD8+ lymphocyte dose in the autograft predicts early absolute lymphocyte count recovery after peripheral hematopoietic stem cell transplantation. Am J Hematol 2009; 84: 21-8.
174. Dean R, Masci P, Pohlman B, et al. Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lympho-ma: graft content and post transplant recovery predict survival. Bone Marrow Transplant 2005; 36: 1049-52. (Pubitemid 43078132)
175. Hiwase DK, Hiwase S, Bailey M, et al. The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple mye-loma. Cytotherapy 2008; 10: 507-17.
176. Katipamula R, Porrata LF, Gastineau DA, et al. Apheresis instrument settings influence infused absolute lymphocyte count affecting survival following autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma: the need to optimize instrument setting and define a lymphocyte collection target. Bone Marrow Transplant 2006; 37: 811-7.
177. Meehan KR, Talebian L, Wu J, et al. Immune mobilization of autologous blood progenitor cells: direct influence on the cellular subsets collected. Cytotherapy 2010; 12: 1013-21.
178. Talebian L, Wu JY, Fischer DA, et al. Novel mobilization strategies to enhance autologous immune effector cells in multiple myeloma. Front Biosci (Elite Ed) 2011; 3: 1500-8.
179. Alici E, Sutlu T, Bjorkstrand B, et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant compo-nents. Blood 2008; 111: 3155-62.
180. Meehan KR, Wu J, Webber SM, et al. Development of a clinical model for ex vivo expansion of multiple populations of effector cells for adoptive cellular therapy. Cytotherapy 2008; 10: 30-7.
181. Meehan KR, Wu A, Hassan R, et al. Ex vivo cytokine activation of peripheral blood stem cells: a potential role for adoptive cellular im-munotherapy. J Hematother Stem Cell Res 2001; 10: 283-90. (Pubitemid 32423552)
182. Burns LJ, Weisdorf DJ, De For TE, et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant 2003; 32: 177-86. (Pubitemid 36903442)
183. Elquza E, Spier C, Fiederlein R, et al. Effects of mobilisation with granulocyte colony stimulating factor (G-CSF) and plerixafor on lym-phocyte subsets in autologous peripheral blood stem cell (PBSC) apher-esis products. ASH Annual Meeting Abstracts 2009; 114: 2145.
184. Takahashi Y, Chakrabarti S, Sriniivasan R, et al. A Detailed phenotypic analysis using six color flow cytometry of lymphocyte subsets mobilised with AMD3100 compared to G-CSF. ASH Annual Meeting Abstracts 2004; 104: 408.
185. Holtan S, Porrata L, Inwards D, et al. Effect of AMD3100 on T lymphocyte subpopulations in apheresis products of patients undergoing autologous hematopoietic stem cell transplantation for non Hodgkin lymphoma. ASH Annual Meeting Abstracts 2005; 106: 2918.
186. Holtan SG, Porrata LF, Micallef IN, et al. AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma. Clin Lymphoma Myeloma 2007; 7: 315-8. (Pubitemid 46408198)
187. Merad M,Manz MG.Dendriticcellhomeostasis. Blood2009; 113: 3418-27.
188. Jongbloed SL, Kassianos AJ, McDonald KJ, et al. Human CD141 + (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010; 207: 1247-60.
189. Piccioli D, Tavarini S, Borgogni E, et al. Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets. Blood 2007; 109: 5371-9. (Pubitemid 46890559)
190. Hart DN, Clark GJ, Dekker JW, et al. Dendritic cell surface molecules. A proliferating field. Adv Exp Med Biol 1997; 417: 439-42. (Pubitemid 27427782)
191. Maraskovsky E, Brasel K, Teepe M, et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 1996; 184: 1953-62. (Pubitemid 26404485)
192. Vuckovic S, Kim M, Khalil D, et al. Granulocyte-colony stimulating factor increases CD123hi blood dendritic cells with altered CD62L and CCR7 expression. Blood 2003; 101: 2314-7. (Pubitemid 36302075)
193. Pulendran B, Banchereau J, Burkeholder S, et al. Flt3-ligand and gran-ulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J Immunol 2000; 165: 566-72. (Pubitemid 30429552)
194. Maraskovsky E, Daro E, Roux E, et al. In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood 2000; 96: 878-84. (Pubitemid 30616851)
195. Arpinati M, Green CL, Heimfeld S, et al. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000; 95: 2484-90. (Pubitemid 30210524)
196. Mac Donald KP, Rowe V, Filippich C, et al. Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplan-tation. Blood 2003; 101: 2033-42. (Pubitemid 36237611)
197. Mac Donald KP, Rowe V, Clouston AD, et al. Cytokine expanded myeloid precursors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells. J Immunol 2005; 174: 1841-50. (Pubitemid 40223923)
198. Morris ES, Mac Donald KP, Rowe V, et al. Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance. Blood 2004; 103: 3573-81. (Pubitemid 38525696)
199. Gazitt Y, Freytes CO, Akay C, et al. Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony- stimulating factor in non-Hodgkin's lymphoma patients. Stem Cells Dev 2007; 16: 657-66. (Pubitemid 47378738)
200. Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008; 112: 990-8.
201. Salem ML, El-Naggar SA, Cole DJ. Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo. Cell Immunol 2010; 261: 134-43.
202. Salem ML, Al-Khami AA, El-Naggar SA, et al. Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells. J Immunol 2010; 184: 1737-47.
203. Salem ML, Cole DJ. Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccina-tion. Cancer Immunol Immunother 2010; 59: 341-53.
204. Nakahara T, Uchi H, Lesokhin AM, et al. Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood 2010; 115: 4384-92.
205. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-Timmunotherapy for castration-resistantprostate cancer. N Engl J Med 2010; 363: 411-22.
206. Rice AM, Jones KL, Hart DN. DC preparations for therapy. Cytotherapy 2004; 6: 99-104. (Pubitemid 38714805)
207. Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immu-notherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007; 7: 790-802. (Pubitemid 47480309)
208. Steinman RM. Dendritic cells in vivo: a key target for a new vaccine science. Immunity 2008; 29: 319-24.
209. Gallois A, Bhardwaj N. A needle in the 'cancer vaccine' haystack. Nat Med 2010; 16: 854-6.
210. Nestle FO, Farkas A, Conrad C. Dendritic-cell-based therapeutic vaccina-tion against cancer. Curr Opin Immunol 2005; 17: 163-9. (Pubitemid 40343103)
211. Pochampally RR, Smith JR, Ylostalo J, Prockop DJ. Serum deprivation of human marrow stromal cells (h MSCs) selects for a subpopulation ofearly progenitor cells with enhanced expression of OCT-4 and other embryonic genes. Blood 2004; 103: 1647-52. (Pubitemid 38268955)
212. Horwitz EM, Le Blanc K, Dominici M, et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 2005; 7: 393-5. (Pubitemid 41671625)
213. Lazarus HM, Haynesworth SE, Gerson SL, Caplan AI. Human bone marrow-derived mesenchymal (stromal) progenitor cells (MPCs) cannot be recovered from peripheral blood progenitor cell collections. JHemato-ther 1997; 6: 447-55.
214. To LB, Russell J, Moore S, Juttner CA. Residual leukaemia cannot be detected in very early remission peripheral blood stem cell collec-tions in acute non-lymphoblastic leukaemia. Leuk Res 1987; 11: 327-9. (Pubitemid 17049392)
215. Henry JM, Sykes PJ, Brisco MJ, et al. Comparison of myeloma cell contamination ofbone marrow and peripheral blood stem cell harvests. Br J Haematol 1996; 92: 614-9. (Pubitemid 26076762)
216. Moss TJ, Sanders DG,Lasky LC, Bostrom B. Contaminationofperipheral blood stem cell harvests by circulating neuroblastoma cells. Blood 1990; 76: 1879-83.
217. Mattano LA Jr, Moss TJ, Emerson SG. Sensitive detection of rare circulating neuroblastoma cells by the reverse transcriptase-polymerase chain reaction. Cancer Res 1992; 52: 4701-5.
218. Ross AA, Cooper BW, Lazarus HM, et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82: 2605-10. (Pubitemid 23318065)
219. Franklin WA, Glaspy J, Pflaumer SM, et al. Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone. Blood 1999; 94: 340-7. (Pubitemid 29300167)
220. Passos-Coelho JL, Ross AA, Kahn DJ, et al. Similar breast cancer cell contamination of single-day peripheral-blood progenitor-cell collections obtained after priming with hematopoietic growth factor alone or after cyclophosphamide followedby growth factor. J Clin Oncol 1996; 14:2569-75. (Pubitemid 26300125)
221. Meldgaard Knudsen L, Jensen L, Gaarsdal E, et al. A comparative study of sequential priming and mobilisation of progenitor cells with rh G-CSF alone and high-dose cyclophosphamide plus rh G-CSF. Bone Marrow Transplant 2000; 26: 717-22.
222. Cremer FW, Kiel K, Wallmeier M, et al. Leukapheresis products in multiple myeloma: lower tumor load after mobilization with cyclopho-sphamide plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone. Exp Hematol 1998; 26: 969-75. (Pubitemid 28405462)
223. Zhou P, Zhang Y, Martinez C, et al. Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination. Blood 2003; 102: 477-9. (Pubitemid 36841963)
224. Fruehauf S, Ehninger G, Hubel K, et al. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplant 2010; 45: 269-75.
225. Gazitt Y, Shaughnessy P, Liu Q. Differential mobilization of CD34+ cells and lymphoma cells in non-Hodgkin's lymphoma patients mobilized with different growth factors. J Hematother Stem Cell Res 2001; 10: 167-76. (Pubitemid 32233702)
226. Stockerl-Goldstein KE, Reddy SA, Horning SF, et al. Favorable treatment outcome in non-Hodgkin's lymphoma patients with 'poor' mobilization of peripheral blood progenitor cells. Biol Blood Marrow Transplant 2000; 6: 506-12.
227. Gertz MA, Witzig TE, Pineda AA, et al. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are asso-ciated with shortened relapse-free survival after transplantation. Bone Marrow Transplant 1997; 19: 337-42. (Pubitemid 27096065)
228. Lemoli RM, Fortuna A, Motta MR, et al. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. Blood 1996; 87: 1625-34.
229. Boccadoro M, Omede P, Dominietto A, et al. Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support. Bone Marrow Transplant 2000; 25: 25-9. (Pubitemid 30093151)
230. Cooper BW, Moss TJ, Ross AA, et al. Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer. J Clin Oncol 1998; 16: 3509-17. (Pubitemid 28506761)
231. Walkley CR, Olsen GH, Dworkin S, et al. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell2007; 129: 1097-110. (Pubitemid 46908696)
232. Raaijmakers MHGP, Mukherjee S, Guo S, et al. Bone progenitor dysfunc-tion induces myelodysplasia and secondary leukaemia. Nature 2010; 464: 852-7.
233. Bonnet D, Dick JE. Human acute myeloid leukaemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-7. (Pubitemid 27298715)
234. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-8. (Pubitemid 24067706)
235. Ninomiya M, Abe A, Katsumi A, et al. Homing, proliferation and survival sites of human leukaemia cells in vivo in immunodeficient mice. Leu-kaemia 2007; 21: 136-42. (Pubitemid 44921844)
236. Ishikawa F, Yoshida S, Saito Y, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007; 25: 1315-21. (Pubitemid 350076512)
237. Kiel MJ, Yilmaz OH, Iwashita T, et al. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 2005; 121: 1109-21. (Pubitemid 40884400)
238. Kohler A, Schmithorst V, Filippi M-D, et al. Altered cellular dynamics and endosteal location of aged early hematopoietic progenitor cells revealed by time-lapse intravital imaging in long bones. Blood 2009; 114: 290-8.
239. Levesque JP, Winkler IG. Hierarchy of immature hematopoietic cells related to blood flow and niche. Curr Opin Hematol 2011; 18: 220-5.
240. Lo Celso C, Fleming HE, Wu JW, et al. Live-animal tracking ofindividual haematopoietic stem/progenitor cells in their niche. Nature 2009; 457: 92-6.
241. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006; 25: 977-88. (Pubitemid 44894948)
242. Xie Y, Yin T, Wiegraebe W, et al. Detection offunctional haematopoietic stem cell niche using real-time imaging. Nature 2009; 457: 97-101.
243. Iwamoto S, Mihara K, Downing JR, et al. Mesenchymal cells regulate the response of acute lymphoblastic leukaemia cells to asparaginase. J Clin Invest2007; 117: 1049-57. (Pubitemid 46556761)
244. Nervi B, Ramirez P, Rettig MP, et al. Chemosensitization of acute myeloid leukaemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009; 113: 6206-14.
245. Buchner M, Baer C, Prinz G, et al. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukaemia. Blood 2010; 115: 4497-506.
246. Colmone A, Amorim M, Pontier AL, et al. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic pro-genitor cells. Science 2008; 322: 1861-5.
247. Shiozawa Y, Pedersen EA, Havens AM, et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 2011; 121: 1298-312.
248. Manabe A, Coustan-Smith E, Behm FG, et al. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukaemia. Blood 1992; 79: 2370-7.
249. Bendall LJ, Daniel A, Kortlepel K, Gottlieb DJ. Bone marrow adherent layers inhibit apoptosis of acute myeloid leukaemia cells. Exp Hematol 1994; 22: 1252-60. (Pubitemid 24369078)
250. Panayiotidis P, Jones D, Ganeshaguru K, et al. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 1996; 92: 97-103. (Pubitemid 26018774)
251. Konopleva M, Konoplev S, Hu W, et al. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukaemia 2002; 16: 1713-24.
252. Juarez J, Bradstock KF, Gottlieb DJ, Bendall LJ. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukaemia cells in vitro. Leukaemia 2003; 17: 1294-300. (Pubitemid 36857336)
253. Burger JA, Kipps TJ. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukaemia B cells. Leuk Lym-phoma 2002; 43: 461-6. (Pubitemid 34232911)
254. Juarez J, Dela Pena A, Baraz R, et al. CXCR4 antagonists mobilize childhood acute lymphoblastic leukaemia cells into the peripheral blood and inhibit engraftment. Leukaemia 2007; 21: 1249-57. (Pubitemid 46831814)
255. Parameswaran R, Yu M, Lim M, Groffen J, Heisterkamp N. Combination of drug therapy in acute lymphoblastic leukaemia with a CXCR4 antago-nist. Leukaemia 2011; Apr 12: (Epub ahead of print).
256. Zeng Z, Shi YX, Samudio IJ, et al. Targeting the leukaemia microenvir-onment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009; 113: 6215-24.
257. Saito Y, Uchida N, Tanaka S, et al. Induction of cell cycle entry eliminates human leukaemia stem cells in a mouse model of AML. Nat Biotechnol 2010; 28: 275-80.
258. Juarez J, Baraz R, Gaundar S, et al. Interaction of interleukin-7 and interleukin-3 with the CXCL12-induced proliferation of B-cell progenitor acute lymphoblastic leukaemia. Haematologica 2007; 92: 450-9. (Pubitemid 350144290)
259. Drummond MW, Heaney N, Kaeda J, et al. A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. Leukaemia 2009; 23: 1199-201.
260. Alexander E, Costa LJ, Taylor M, et al. Cost-effective use of plerixafor for hematopoietic stem cells mobilization: Development and validation of a decision-making algorithm. ASH Annual Meeting Abstracts 2009; 114: Abstr 3216.
261. Abhyankar S, Aljitawi OS, Ganguly N, et al. An algorithmic approach to evaluate the optimal use of Plerixafor (Mozobil(R)) for autologous hematopoietic peripheral blood stem cell (PBSC) collections based on peripheral circulating CD34 counts and day one collection yield in patients with multiple myeloma (MM) and lymphoma (NHL, HD). Biol Blood Marrow Transplant 2010; 16: S164-5.